Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement

Merck & Co Inc (MRK) opened up by 4.50%. The Pharmaceuticals & Medical Research sector is up by 0.44%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Akari Therapeutics PLC (AKTX) up 100.49%; MetaVia Inc (MTVA) up 27.87%; Eli Lilly and Co (LLY) up 0.87%.

What is driving Merck & Co Inc (MRK)’s stock price up today?

Merck & Co. (MRK) experienced significant positive movement in its share price today, largely driven by favorable clinical trial results and a strengthening outlook for its oncology pipeline. The primary catalyst appears to be the announcement of positive Phase III study results for sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate developed in partnership with Kelun Biotech, when used in combination with Keytruda for treating non-small cell lung cancer (NSCLC). This combination therapy demonstrated a substantial reduction in the risk of disease progression or death compared to Keytruda alone, marking a significant advancement in lung cancer treatment options. This success, especially as the first successful Phase III study of an ADC combined with immunotherapy in the first-line treatment of lung cancer, has fueled investor confidence in Merck's strategic initiatives to diversify its portfolio.

Further bolstering positive sentiment, Merck is preparing to present an extensive array of oncology data at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This includes long-term follow-up data for its blockbuster Keytruda and new insights across its rapidly advancing pipeline, underscoring the company's leadership in oncology and commitment to innovative research. The impending ASCO presentations, which will highlight more than 100 abstracts across numerous cancer types, are seen as crucial for demonstrating Merck's ability to maintain revenue growth and mitigate the impact of Keytruda's eventual patent expiration.

Beyond these pipeline developments, the company's recent financial performance has also contributed to a more positive investment climate. Merck reported first-quarter 2026 earnings that surpassed analyst expectations for both earnings per share and revenue. The company also raised its full-year revenue guidance, reflecting underlying operational strength, particularly in its oncology segment, despite the initial market reaction to a one-time acquisition charge. These factors, combined with largely positive analyst ratings and price targets, indicate a robust fundamental backdrop supporting today's share price appreciation.

Technical Analysis of Merck & Co Inc (MRK)

Technically, Merck & Co Inc (MRK) shows a MACD (12,26,9) value of [-1.00], indicating a neutral signal. The RSI at 55.76 suggests neutral condition and the Williams %R at -1.91 suggests oversold condition. Please monitor closely.

Media Coverage of Merck & Co Inc (MRK)

In terms of media coverage, Merck & Co Inc (MRK) shows a coverage score of 49, indicating a moderate level of media attention. The overall market sentiment index is currently in bullish zone.

Fundamental Analysis of Merck & Co Inc (MRK)

Merck & Co Inc (MRK) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $65.01B, ranking 5 in the industry. The net profit is $18.25B, ranking 3 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $129.17, a high of $150.00, and a low of $100.00.

More details about Merck & Co Inc (MRK)

Company Specific Risks:

• The recent failure of the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma, involving a three-drug combination with Welireg, poses a setback to Merck's oncology pipeline expansion and raises concerns about future revenue streams as the patent expiration for its blockbuster drug Keytruda approaches.
• Merck & Co., Inc. recently received a downgrade from "buy" to "hold" by Wall Street Zen in a research report published on May 16th, indicating a less favorable outlook on the company's stock performance by institutional analysts.
• Merck faces an ongoing securities fraud class-action lawsuit alleging that the company made misleading statements concerning the revenue outlook and growth of its Gardasil vaccine, particularly in China, with Merck having filed a motion to dismiss the amended complaint on May 1, 2026.